DOI: 10.1097/inf.0000000000004715 ISSN: 0891-3668
ACTIVE POST-MARKETING SAFETY SURVEILLANCE OF NIRSEVIMAB ADMINISTERED TO CHILDREN IN WESTERN AUSTRALIA, APRIL–JULY 2024
Dale Carcione, Phoebe Spencer, Grace Pettigrew, Alan Leeb, Carla Drake-Brockman, Timothy Ford, Paul EfflerChildren receiving nirsevimab were texted a link to an online survey to monitor adverse events following immunization. Total of 4340 parents received the link, which 1195 (27.5%) responded. Forty-seven (11.4%) of 410 children who received nirsevimab alone and 230 (29.3%) of 785 children who received nirsevimab coadministered reported any reaction. No adverse events required in-patient care or had ongoing sequelae.